(1, 1, 1,3,3,3 -hexafluoro-2 hydroxypropan- 2 -yl) phenyl derivative, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis

A (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivative having the general Formula I

• wherein
• n is 0 or 1;
• X is NR4, O or bond;
• Y is O, CHR5, C(OR6)R5, CO, S, SO, SO2, NR5, CONR5 or a bond, and the dotted bond represents a single bond;
• or
• Y is CR5, and the dotted bond represents a double bond;
• Y has a meta or para substitution pattern on the phenyl ring in relation to the phenyl-NH position;
• Z is CH2 or CO;
• the hexafluoroispopropanol substituent has an ortho, meta or para substitution pattern on the phenyl ring in relation to the phenyl-Z position;
• R1 is (C1-8)alkyl, (C3-8)cycloalkyl or (C3-8)cycloalkyl(C1-4alkyl, each of the alkyl groups being optionally substituted by 1 or 2 substituents selected from hydroxy, hydroxymethyl, (C1-3)alkyloxy, cyano, halogen, CF3, NR7R8, NR7R8CO and R9OCO;
• or
• R1 is 5- or 6-membered aromatic ring, optionally comprising 1-3 heteroatoms selected from O, S and N, the ring being optionally substituted by (C1-3)alkyl,
• (C3-6)cycloalkyl, (C1-3)alkyloxy, (C1-3)alkylsulfonyl, cyano, CF3, OCF3, halogen or R9OCO, and the ring being optionally linked to X via a (C1-3)alkylene group which is optionally substituted by hydroxy;
• or
• R1 is a 4-, 5- or 6-membered saturated or unsaturated heterocyclic ring, comprising 1 or 2 heteroatoms selected from NR10, O, S, SO and SO2, the ring being optionally substituted by (C1-3)alkyl, hydroxy, oxo, NR11R12 or R9OCO, and the ring being optionally linked to X via a (C1-3)alkylene group which is optionally substituted by hydroxy;
• or
• when X is NR4, R1 may together with R4 and the N to which they are bonded form a 4-8 membered ring, which can be optionally substituted with hydroxyl or hydroxymethyl;
• R2 is H or 1-3 halogens;
• or
• when Y is NR5, R2 and R5 may together with the 2 adjacent carbon atoms to which they are bonded form a fused 5-membered heteroaromatic ring, optionally comprising 1 or 2 additional N atoms;
• R3 is H or (C1-3)alkyl;
• R1, when present, is H or (C1-3)alkyl;
• R5, when present, is H or (C1-3)alkyl;
• R6, when present, is H or (C1-3)alkyl;
• R7 and R8, when present, are independently H or (C1-3)alkyl;
• R9, when present, is H or (C1-3)alkyl;
• R10, when present, is H or (C1-3)alkyl;
• R11 and R12, when present, are independently H or (C1-3)alkyl;
• or a pharmaceutically acceptable salt thereof.